2024 World Conference on Lung Cancer (WCLC) - Posters-P1.03F.02 Establishment of EBUS-TBNA Sample Derived Lung Cancer Organoid and Xenograft and Utility for Development of Targeted Therapy

P1.03F.02 Establishment of EBUS-TBNA Sample Derived Lung Cancer Organoid and Xenograft and Utility for Development of Targeted Therapy

Back to course

Pdf Summary

This study aimed to establish lung cancer organoids and patient-derived xenografts (PDX) from advanced lung cancer samples using Endobronchial Ultrasound with Transbronchial Needle Aspiration (EBUS-TBNA), a routine biopsy method. While patient-derived organoids (PDO) and PDX models are established preclinical tools, the emphasis has typically been on early-stage lung cancer derived from resected tumors. This study focuses on applying such models to advanced lung cancers.<br /><br />Researchers successfully developed lung cancer organoids and PDX models from EBUS-TBNA biopsy samples. These models replicated the characteristics of the original tumors, suggesting their potential for studying the biology of advanced lung cancer and evaluating drug responses in a preclinical setting.<br /><br />In conducting this study, the team identified four instances of non-cancer cell growth during model establishment, ensuring that the resulting models were free from contamination by non-cancer cells. From 71 lung cancer samples, they produced six stable organoids (including three from lung adenocarcinoma (LUAD) and three from small cell lung cancer (SCLC)), with a success rate of 8.5%. Additionally, they created 20 stable PDX models from 106 samples (18.9% success rate) and 14 stable xenograft-derived organoid (XDO) models.<br /><br />Drug sensitivity tests revealed heterogeneous responses in models with HER2-altered cancer, with a notable response to HER2-targeted therapies in some PDO models. Consistent drug responses were observed across PDO, PDX, and XDO models from the same patient. The study also identified a potent response to MEK inhibitors in a rare MAP2K mutation-bearing XDO model.<br /><br />This research highlights the potential of EBUS-derived organoids and xenografts in developing targeted therapies for advanced lung cancer, providing a platform for drug screening and personalized medicine approaches.

Asset Subtitle

Takamasa Koga

Meta Tag

Speaker Takamasa Koga

Topic Tumor Biology – Translational Biology

Keywords

lung cancer

organoids

xenografts

EBUS-TBNA

advanced cancer

drug response

HER2-targeted therapy

MEK inhibitors

personalized medicine

preclinical models